Literature DB >> 12851652

Role of chemokines in angiogenesis: CXCL12/SDF-1 and CXCR4 interaction, a key regulator of endothelial cell responses.

Rosalba Salcedo1, Joost J Oppenheim.   

Abstract

Chemokines are small proteins that act as cell attractants via the activation of G protein-coupled receptors. Chemokines play an important role in several pathophysiological processes such as inflammation and immunity. Many proinflammatory chemokines also support the development of vascular blood supply at the site of inflammation. Similarly, tumor-generated chemokines can contribute to tumor growth by promoting angiogenesis. Recently, significant advances have been made in understanding the contribution of chemokines to the angiogenesis process. This review will discuss first the evidence supporting the direct contribution of different chemokine subfamily members, including CC, CXC, and CX3C chemokines, as positive or negative regulators of the angiogenesis process based on the expression of their cognate receptors on endothelial cells. Additionally, the relationship between classic angiogenic factors and chemokine receptor expression on endothelial cells, and the implications of chemokine production by cancer cells will be analyzed with particular emphasis on the CXCL12/stromal-cell derived factor-1 interaction with CXCR4.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12851652     DOI: 10.1038/sj.mn.7800200

Source DB:  PubMed          Journal:  Microcirculation        ISSN: 1073-9688            Impact factor:   2.628


  95 in total

1.  Down-regulation of CXCL12 by DNA hypermethylation and its involvement in gastric cancer metastatic progression.

Authors:  Yu Zhi; Jing Chen; Shuanglong Zhang; Xiaojing Chang; Jingguo Ma; Dongqiu Dai
Journal:  Dig Dis Sci       Date:  2011-09-29       Impact factor: 3.199

Review 2.  The role of CXC chemokines in pulmonary fibrosis.

Authors:  Robert M Strieter; Brigitte N Gomperts; Michael P Keane
Journal:  J Clin Invest       Date:  2007-03       Impact factor: 14.808

Review 3.  Chemokines in tumor angiogenesis and metastasis.

Authors:  Seema Singh; Anguraj Sadanandam; Rakesh K Singh
Journal:  Cancer Metastasis Rev       Date:  2007-12       Impact factor: 9.264

4.  Baclofen and other GABAB receptor agents are allosteric modulators of the CXCL12 chemokine receptor CXCR4.

Authors:  Alice Guyon; Amanda Kussrow; Ian Roys Olmsted; Guillaume Sandoz; Darryl J Bornhop; Jean-Louis Nahon
Journal:  J Neurosci       Date:  2013-07-10       Impact factor: 6.167

Review 5.  Chemokines and chemokine receptors: update on utility and challenges for the clinician.

Authors:  Ishan Roy; Douglas B Evans; Michael B Dwinell
Journal:  Surgery       Date:  2014-02-08       Impact factor: 3.982

Review 6.  Cancer stem cells, cancer cell plasticity and radiation therapy.

Authors:  Erina Vlashi; Frank Pajonk
Journal:  Semin Cancer Biol       Date:  2014-07-12       Impact factor: 15.707

7.  mTORC2 mediates CXCL12-induced angiogenesis.

Authors:  Mary E Ziegler; Michaela M S Hatch; Nan Wu; Steven A Muawad; Christopher C W Hughes
Journal:  Angiogenesis       Date:  2016-04-22       Impact factor: 9.596

8.  Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines.

Authors:  Jingting Mai; Fei Wang; Qiong Qiu; Buzhou Tang; YongQing Lin; NianSang Luo; WoLiang Yuan; XiaoLong Wang; Qingcai Chen; JingFeng Wang; YangXin Chen
Journal:  Heart Vessels       Date:  2014-12-10       Impact factor: 2.037

Review 9.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

10.  Association of monocyte chemoattractant protein-1 (MCP-1)2518A/G polymorphism with proliferative diabetic retinopathy in northern Chinese type 2 diabetes.

Authors:  Li Dong; Xiao Ying Lv; Bin Jie Wang; Ye Qing Wang; Hua Mu; Zhuo Lei Feng; Ping Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-05-09       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.